Previous | Next
732733734735736737738739740741742743744745746747748749750751752753754755756757758759760761762763764765766767768769770771772773774775776777778779780781782783784785786787788789790791792 of 999
Either you'll get a very good result, or you'll find
that something else in the material is helping. We don't know.
So it's a great --
It's very promising.
It's very promising and also very nerve wracking, to
find out whether interferon alone is doing what we see in .1 of
1 percent pure product.
Well, simultaneously, are they continuing to work with it
in Finland and elsewhere in Europe?
And what results are they getting there?
Well, in Finland they don't do any clinical research. They
sell their material all over the world. Any minute the Finnish
government may say, “Oh well, we're going to keep all this in
Finland,” but at present they're still supplying researchers, and
the Swedes have got very good reults in osteogenic sarcoma, and
in myeloma, and in some, a few lymphomas. They've had very
striking responses, and they estimate that their results in
osteogenic sarcoma (or bone cancer) in children or young people will
result in a 50 percent disease free survival at five years. Now,
if this material, plus the material that we're using like
methotrexate and other more toxic drugs, were put together with
interferon, you could have cures.
You could certainly have cures. And so this is what
drives one to want to have enough material, pure material and
also, to try to raise a lot of money to have even just the kind
of material we have, as it is already prolonging life in some
© 2006 Columbia University
Libraries | Oral History
Research Office | Rights and
Permissions | Help